Intelligence Feed event · Equity · 2026-09-03

    Fortrea to Acquire Worldwide Clinical Trials Early Phase Unit for $45M

    Question

    Fortrea to Acquire Worldwide Clinical Trials Early Phase Unit for $45M

    Direct answer

    Contract research organization Fortrea announced a definitive agreement to acquire the Early Phase Services unit from Worldwide Clinical Trials for approximately $45 million. The deal expands Fortrea's early-stage drug development infrastructure. The acquired assets comprise a 200-bed Phase 1 clinical pharmacology unit in San Antonio, a bioanalytical testing laboratory in Austin compliant with Good Laboratory Practice (GLP) standards, and biospecimen storage facilities in Pflugerville, enhancing Fortrea's high-margin bioanalytical throughput.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Fortrea to Acquire Worldwide Clinical Trials Early Phase Unit for $45M”, revision 1, evidence through 2026-09-03. https://marketontology.com/market-events/2026-09-03/fortrea-to-acquire-worldwide-clinical-trials-early-phase-unit-for-45m-26ad74

    EQUITY
    Fortrea to Acquire Worldwide Clinical Trials Early Phase Unit for $45M
    Contract research organization Fortrea announced a definitive agreement to acquire the Early Phase Services unit from Worldwide Clinical Trials for approximately $45 million. The deal expands Fortrea's early-stage drug development infrastructure. The acquired assets comprise a 200-bed Phase 1 clinical pharmacology unit in San Antonio, a bioanalytical testing laboratory in Austin compliant with Good Laboratory Practice (GLP) standards, and biospecimen storage facilities in Pflugerville, enhancing Fortrea's high-margin bioanalytical throughput.
    FTRE
    Impact
    63
    SEP 3
    SIG
    90%
    FTRE
    Fortrea to Acquire Worldwide Clinical Trials Early Phase Unit for $45M
    Contract research organization Fortrea announced a definitive agreement to acquire the Early Phase Services unit from Worldwide Clinical Trials for approximately $45 million. The deal expands Fortrea's early-stage drug development infrastructure. The acquired assets comprise a 200-bed Phase 1 clinical pharmacology unit in San Antonio, a bioanalytical testing laboratory in Austin compliant with Good Laboratory Practice (GLP) standards, and biospecimen storage facilities in Pflugerville, enhancing Fortrea's high-margin bioanalytical throughput.
    → Acquiring clinical pharmacology capacity at a $45M valuation increases Fortrea's early-stage CRO pipeline capacity and service margins.
    Impact
    Contract research organization Fortrea announced a definitive agreement to acquire the Early Phase Services unit from Worldwide Clinical Trials for approximately $45 million. The deal expands Fortrea's early-stage drug development infrastructure. The acquired assets comprise a 200-bed Phase 1 clinical pharmacology unit in San Antonio, a bioanalytical testing laboratory in Austin compliant with Good Laboratory Practice (GLP) standards, and biospecimen storage facilities in Pflugerville, enhancing Fortrea's high-margin bioanalytical throughput.
    Affected
    FTRE
    Transmission
    Acquiring clinical pharmacology capacity at a $45M valuation increases Fortrea's early-stage CRO pipeline capacity and service margins.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    FTREcapacity addition to early-stage CRO pipeline and revenue baseUp1-4wAcquired Early Phase Services unit for $45 million to expand clinical pharmacology footprint.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month